# CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Source: https://onco.cc/trials/nct05218408/  
OnCo record `nct05218408` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CYNK-001 run by Celularity Incorporated, withdrawn before enrolling.

## Summary

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type is a phase 1/2 interventional study registered as NCT05218408 by Celularity Incorporated, started 2021-09. Conditions recorded: Astrocytoma, Grade IV, Glioblastoma, Giant Cell Glioblastoma and Glioblastoma Multiforme. Interventions recorded: CYNK-001 systemic and Intra cavity administration.

## Fields

- Kind: Trial
- Status: withdrawn
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05218408
- Phase: 1/2
- Setting: A Phase I/IIa Open Label Multicenter, Non-Randomized, Trial to Assess the Safety and Efficacy of CYNK-001in Combination With Recombinant Human Interleukin-2 in Adults With Recurrent Resection Eligible IDH1 Wild-type Glioblastoma
- Sponsor: Celularity Incorporated

## Sources

- ClinicalTrials.gov NCT05218408: https://clinicaltrials.gov/study/NCT05218408

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [CYNK-001](https://onco.cc/drugs/cynk-001/)
- companies: [Celularity](https://onco.cc/companies/celularity/)

---
JSON: https://onco.cc/api/v1/entities/nct05218408.json